Company Filing History:
Years Active: 2020-2024
Title: Innovations by Yong-Hee Rhee in Cancer Treatment
Introduction
Yong-Hee Rhee is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of cancer treatment through his innovative methods and compositions. With a total of 4 patents, Rhee's work focuses on harnessing the power of immune cells to combat cancer effectively.
Latest Patents
One of Rhee's latest patents is a method for producing natural killer cells and a composition for treating cancer. This method involves isolating peripheral blood mononuclear cells (PBMCs) from a blood sample, followed by isolating CD56+ cells and/or CD3−/CD56+ cells from the PBMCs. The isolated cells are then co-cultured with a combination of feeder cells in the presence of a cytokine. The resulting composition comprises the CD56+ natural killer cells produced by this method along with a cytokine, providing a novel approach to cancer treatment. Another significant patent involves pharmaceutical compositions and methods that include immune cells pretreated with ponatinib. This method enhances the survival and anti-cancer cytotoxicity of the immune cells, showcasing Rhee's commitment to advancing cancer therapies.
Career Highlights
Yong-Hee Rhee is associated with Nkmax Co., Ltd., where he continues to innovate in the field of immunotherapy. His work has garnered attention for its potential to improve cancer treatment outcomes. Rhee's dedication to research and development has positioned him as a key figure in the fight against cancer.
Collaborations
Rhee collaborates with talented individuals in his field, including Sang Woo Park and Yong Man Kim. Their combined expertise contributes to the advancement of innovative cancer therapies.
Conclusion
Yong-Hee Rhee's contributions to cancer treatment through his innovative patents highlight the importance of research in developing effective therapies. His work continues to inspire advancements in the medical field, offering hope for improved cancer treatments in the future.